White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’

White House officials on Tuesday shot down a report speculating that President Trump gained access to the retatrutide weight-loss drug under the Food and Drug Administration’s (FDA) “compassionate use program.”

The retatrutide drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that approves experimental treatments for patients traditionally suffering from life-threatening illnesses. 

Three anonymous sources familiar with the matter told STAT News, the patient approved to receive retatrutide was 79 years old, leading the outlet to believe the prescription could have been issued to Trump who turned 80 last week. 

“Because this has to be spelled out for @LizzyLaw, who has proven herself to be an unserious gossip columnist, this application was not for the President,” White House senior deputy press secretary Kush Desai wrote in a Tuesday post on X, referring to reporter Lizzy Lawrence who authored the........

© The Hill